ADXS31-164

· Advaxis, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ADXS31-164, covering 2020-07-16 to 2020-07-16. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors [Phase 1, Phase 2]